ZNF430, a protein belonging to the zinc finger protein family, is a transcription factor implicated in the regulation of gene expression and various cellular processes. As a member of the Krüppel-like zinc finger protein family, ZNF430 contains multiple zinc finger motifs that enable it to bind to specific DNA sequences, thereby modulating the transcription of target genes. While the precise function of ZNF430 remains incompletely elucidated, it is proposed to play a role in diverse biological processes, including development, differentiation, and cell cycle regulation. Additionally, ZNF430 has been implicated in the regulation of apoptosis and DNA repair mechanisms, highlighting its involvement in maintaining cellular homeostasis and integrity.
The activation of ZNF430 likely involves intricate regulatory mechanisms that govern its expression, post-translational modifications, and interactions with other proteins and regulatory molecules. One mechanism of ZNF430 activation may involve signaling pathways that regulate its transcriptional activity in response to extracellular stimuli or intracellular signals. For example, growth factor signaling pathways such as the MAPK/ERK or PI3K/Akt pathways may phosphorylate ZNF430 or regulate its nuclear translocation, thereby activating its transcriptional function. Furthermore, ZNF430 activation may be modulated by interactions with co-regulators or chromatin-modifying enzymes that influence its DNA-binding affinity and transcriptional activity. Additionally, epigenetic modifications such as histone acetylation or DNA methylation may regulate the accessibility of ZNF430 target genes, thereby modulating its transcriptional activity. Elucidating the precise mechanisms underlying ZNF430 activation will provide valuable insights into its physiological roles and its implications in development, disease, and cellular homeostasis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin stimulates the production of cAMP, which can activate PKA. PKA, in turn, can phosphorylate a variety of proteins including ZNF430, leading to its enhanced activity. | ||||||
Adenosine 3′,5′-cyclic monophosphate | 60-92-4 | sc-217584 sc-217584A sc-217584B sc-217584C sc-217584D sc-217584E | 100 mg 250 mg 5 g 10 g 25 g 50 g | $114.00 $175.00 $260.00 $362.00 $617.00 $1127.00 | ||
cAMP, a secondary messenger, can directly activate Protein Kinase A (PKA). Following activation, PKA can phosphorylate ZNF430, enhancing its functional activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, which break down cAMP. By inhibiting these enzymes, IBMX raises the levels of cAMP, which can activate PKA to enhance ZNF430 activity. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $97.00 $224.00 | 30 | |
8-Bromo-cAMP is a cell-permeable cAMP analog. It can activate PKA which can phosphorylate and enhance ZNF430 activity. | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $92.00 $182.00 | 71 | |
H-89 is a potent and selective inhibitor of Protein Kinase A (PKA). By inhibiting PKA activity, H-89 can indirectly enhance the activity of ZNF430. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. It can inhibit PKA, leading to an indirect increase in ZNF430 activity through altered phosphorylation states. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits PI3K, which can dampen the Akt pathway. A decrease in Akt activity can enhance the activity of ZNF430. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor which can decrease Akt activity, leading to enhanced ZNF430 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which can lead to decreased Akt activity. This decrease can indirectly enhance ZNF430 activity. | ||||||
BEZ235 | 915019-65-7 | sc-364429 | 50 mg | $207.00 | 8 | |
BEZ235 inhibits both PI3K and mTOR, leading to decreased Akt activity and enhanced ZNF430 activity. | ||||||